Log in with your email address username.


[Comment] New-generation JAK inhibitors: how selective can they be?

Almost 20 years into the biologics era, an unmet need exists for treating patients with rheumatoid arthritis and other inflammatory diseases who either do not tolerate, do not respond to, or cannot afford effective but costly biologic medicines. Also 20 years ago, the small family of Janus kinases (or tyrosine-protein kinase JAK; JAKs) were discovered, and have since been harnessed for treating and understanding both malignancies and inflammatory diseases.